HK1253036A1 - 作為毒蕈碱m1和/或m4受體的激動劑的肟化合物 - Google Patents

作為毒蕈碱m1和/或m4受體的激動劑的肟化合物

Info

Publication number
HK1253036A1
HK1253036A1 HK18112415.2A HK18112415A HK1253036A1 HK 1253036 A1 HK1253036 A1 HK 1253036A1 HK 18112415 A HK18112415 A HK 18112415A HK 1253036 A1 HK1253036 A1 HK 1253036A1
Authority
HK
Hong Kong
Prior art keywords
muscarinic
agonists
receptor
oxime compounds
oxime
Prior art date
Application number
HK18112415.2A
Other languages
English (en)
Inventor
Giles Albert Brown
Benjamin Gerald Tehan
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of HK1253036A1 publication Critical patent/HK1253036A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18112415.2A 2015-11-02 2018-09-27 作為毒蕈碱m1和/或m4受體的激動劑的肟化合物 HK1253036A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1519352.7A GB201519352D0 (en) 2015-11-02 2015-11-02 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
HK1253036A1 true HK1253036A1 (zh) 2019-06-06

Family

ID=55130557

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112415.2A HK1253036A1 (zh) 2015-11-02 2018-09-27 作為毒蕈碱m1和/或m4受體的激動劑的肟化合物

Country Status (11)

Country Link
US (2) US11208396B2 (zh)
EP (2) EP3797778A1 (zh)
JP (1) JP6799596B2 (zh)
CN (1) CN108290055B (zh)
AU (1) AU2016348847B2 (zh)
CA (1) CA3003669C (zh)
DK (1) DK3370828T3 (zh)
ES (1) ES2804774T3 (zh)
GB (1) GB201519352D0 (zh)
HK (1) HK1253036A1 (zh)
WO (1) WO2017077292A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402405QA (en) 2011-11-18 2014-09-26 Heptares Therapeutics Ltd Muscarinic m1 receptor agonists
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
EP3394061B1 (en) 2015-12-23 2020-03-11 Merck Sharp & Dohme Corp. 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
CN110944999A (zh) * 2017-08-01 2020-03-31 勃林格殷格翰国际有限公司 中间体化合物和方法
JP2020537667A (ja) 2017-10-17 2020-12-24 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
US11352344B2 (en) 2017-10-31 2022-06-07 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
AU2020361735B2 (en) 2019-10-09 2024-04-18 Novartis Ag 2-azaspiro(3.4)octane derivatives as M4 agonists
PE20221454A1 (es) 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaespiro[3.4]octano como agonistas de m4

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
AU780983B2 (en) * 1999-05-04 2005-04-28 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
AU776541B2 (en) 1999-05-04 2004-09-16 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
ATE428422T1 (de) 2004-02-05 2009-05-15 Schering Corp Piperidin-derivate als ccr3-antagonisten
WO2006058294A2 (en) * 2004-11-29 2006-06-01 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
SG11201402405QA (en) * 2011-11-18 2014-09-26 Heptares Therapeutics Ltd Muscarinic m1 receptor agonists
US9266857B2 (en) * 2012-09-18 2016-02-23 Heptares Therapeutics Limited Bicyclic AZA compounds as muscarinic M1 receptor agonists
WO2014122474A1 (en) * 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
KR102352388B1 (ko) * 2014-02-06 2022-01-17 헵테얼즈 테라퓨틱스 리미티드 무스카린성 m1 수용체 및/또는 m4 수용체 작용제로서 바이사이클릭 아자 화합물

Also Published As

Publication number Publication date
CA3003669C (en) 2024-04-09
EP3370828B1 (en) 2020-04-15
JP6799596B2 (ja) 2020-12-23
EP3797778A1 (en) 2021-03-31
EP3370828A1 (en) 2018-09-12
US20220298133A1 (en) 2022-09-22
GB201519352D0 (en) 2015-12-16
US11208396B2 (en) 2021-12-28
JP2018536653A (ja) 2018-12-13
US20200165220A1 (en) 2020-05-28
WO2017077292A1 (en) 2017-05-11
DK3370828T3 (da) 2020-07-13
CN108290055A (zh) 2018-07-17
CA3003669A1 (en) 2017-05-11
AU2016348847A1 (en) 2018-06-07
CN108290055B (zh) 2021-05-14
AU2016348847B2 (en) 2021-07-08
ES2804774T3 (es) 2021-02-09

Similar Documents

Publication Publication Date Title
HK1253036A1 (zh) 作為毒蕈碱m1和/或m4受體的激動劑的肟化合物
HK1248218A1 (zh) 作為毒蕈碱m1受體和/或m4受體的激動劑的螺環化合物
HK1231473A1 (zh) 作為毒蕈碱 和/或 受體激動劑的雙環氮雜化合物
HK1250160A1 (zh) 毒蕈碱激動劑
IL248347B (en) Compounds and preparations as agonists of toll-like receptor 7
IL248311B (en) Compounds and preparations as agonists of toll-like receptor 7
HK1255163A1 (zh) 作為apj受體激動劑的雜芳基羥基嘧啶酮
HK1250139A1 (zh) 毒蕈碱激動劑
IL247854A0 (en) Muscarinic receptor antagonists, preparations containing them and their uses
HK1250138A1 (zh) 毒蕈碱激動劑
IL254476A0 (en) Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists
IL282088A (en) Ergoline compounds and their uses
GB201519128D0 (en) Solid forms and methods of preparing the same
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
HK1247136A1 (zh) 包含15-hepe的組合物和其使用方法
EP3265466A4 (en) Peripheral-anticholinergic muscarinic agonist combination
EP3203992A4 (en) Compositions and methods for increasing the bioavailability of one or more compounds
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
IL251588A0 (en) Methods and preparations for increasing the potency of antifungal agents
ZA201608823B (en) Processes for the preparation of azd5363 and novel intermediate used therein